Research and development status
Kelun Pharmaceuticals has long spared no effort to build innovative pharmaceutical enterprises, training and introduction of a number of academic leaders with high academic attainments, has now established a highly effective innovation team. At the same time constantly strengthen the investment in research and development work, the formation of a stronger and stronger mall game power. Scientific and technological innovation is the core competitiveness of Kelun, as early as 1998 Kelun Pharmaceuticals established Chengdu Kelun Drug Research Institute (renamed as Sichuan Kelun Drug Research Co., Ltd. in January 2007), which specializes in research, development and technology transfer of pharmaceuticals, and is an independent legal entity subordinate to Sichuan Kelun Pharmaceutical Co. As a research and development center, it is the direct support unit of National Postdoctoral Research Station of Kelun Pharmaceuticals. As of December 2011, **** has obtained 81 new drug certificates and applied for 519 patents, including 192 invention patents.
On October 30, 2009, the Ministry of Science and Technology approved Kelun Pharmaceuticals to set up the National Engineering and Technology Research Center for High-Capacity Injectable Drugs; on November 6, 2009, it was jointly recognized as a Nationally Recognized Enterprise Technology Center by the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation; and in 2011, it set up the Enterprise Academician Workstation. It has a standard laboratory of 3,000m2; 4 pilot plants of 4,500m2, including glass vial large volume injections, plastic vial large volume injections, small volume injections and lyophilized powder injections (except for small volume injections, all of which have passed the GMP certification of SFDA); and 446 sets of experimental research and pilot plant equipments, with the original value of equipment of 64,580,000 RMB. It can undertake the research and development, small and medium trials of various new drugs, providing favorable conditions for carrying out the experimental development of new products.
Kelun focuses on the research and development of innovative drugs, focusing on the research and development of Class I new drugs in the fields of antibacterial, antiviral, anti-tumor, treatment of psychiatric diseases, treatment of cardiovascular and cerebral vascular diseases, etc. At present, there are 8 Class I new drugs being independently and cooperatively researched and developed.
Kelun has now formed a variety of dosage forms, mainly for the research and development of I.V. infusion, as well as for the research and development of APIs, tablets, capsules, granules, drops, eye drops, ear drops, combinations, small-volume injections, powdered needles, and traditional Chinese medicines, etc., and it is a new drug research and development organization with stronger research and development strength in the western region of China, as well as advanced supporting equipments. Kelun Pharmaceuticals actively carries out cooperation between industry, academia and research, the company carries out extensive exchanges and cooperation with domestic and foreign universities and scientific research institutes, and has formed a knowledge alliance strategic partnership, which further improves the strength of research and development. We have established extensive, in-depth and long-term cooperation with more than 20 domestic and foreign pharmaceutical research institutes, including Peking University, China Pharmaceutical University, Shenyang Pharmaceutical University, Sichuan University, Second Military Medical University, Jiangxi College of Traditional Chinese Medicine, Chengdu University of Traditional Chinese Medicine, Sichuan Academy of Traditional Chinese Medicine, Sichuan Antimicrobial Industry Research Institute, and Frontage Laboratories Co. Ltd, USA.
Business Scope
Research and development of new drugs, generic drugs and technical research for the company's subsidiaries.
Accept R&D work entrusted by external organizations.
Direction of R&D
Research and development of infusion varieties with good market prospects
Research and development of new packaging for infusion
Research and development of OTC products with precise efficacy and low toxicity and side-effects
Research and development of brand new medicines with independent intellectual property rights
Research and development of new dosage forms of medicines
Research and development of new compound preparation
Carrying out secondary development of existing famous and excellent pCms to promote the modernization of Chinese medicine